We're expanding our use of data and analytics to identify members who may be in the early stages of opioid addiction.
The BCBSIL Controlled Substance Integration (CSI) program brings pharmacists, doctors, special investigations staff, behavioral health specialists and case managers together to identify causes that may lead to drug abuse and help improve member health and wellness.
The CSI member program builds upon BCBSIL’s Controlled Drug Substance program, in which members are identified based on factors that may affect patient safety or when they require additional intervention. Using a multidisciplinary approach, identified members undergo a comprehensive evaluation and a plan of action is executed.
The CSI provider program analyzes prescribing data and informs providers if members are using multiple prescribers and/or pharmacies for controlled substances. When we monitor providers after engaging them with this approach, we see an average 15mg reduction in morphine equivalent daily dose per patient.